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The objective of this work was to develop and validate a rapid high performance liquid chromatography 
(HPLC) method for the quantitative analysis of fluorouracil (5-FU) in polymeric nanoparticles. 
Chromatographic analyses were performed on an RP C18 column with a mobile phase consisting of 
acetonitrile and water (10:90, v/v) at a flow rate of 1 mL/min. The 5-FU was detected and quantitated 
using a photodiode array detector at a wavelength of 265 nm. The method was shown to be specific and 
linear in the range of 0.1-10 μg/mL (r = 0.9997). The precision (intra- and inter-day) was demonstrated 
because the maximum relative standard deviation was 3.51%. The method is robust relative to 
changes in flow rate, column and temperature. The limits of detection and quantitation were 10.86 and  
32.78 ng/mL, respectively. The method fulfilled the requirements for reliability and feasibility for 
application to the quantitative analysis of 5-FU in polymeric nanoparticles.
Uniterms: Fluorouracil/determination. Nanoparticles. High performance liquid chromatography/
quantitative analysis/method validation.
O objetivo deste trabalho foi desenvolver e validar um método rápido de cromatografia líquida de alta 
eficiência (CLAE) para análise quantitativa de fluorouracila (5-FU) em nanopartículas poliméricas. 
Corridas cromatográficas foram realizadas sob uma coluna RP C18 com uma fase móvel consistindo de 
acetonitrila e água (10:90, v/v) a um fluxo de 1 mL/min. O 5-FU foi detectado e quantificado através de 
um detector de fotodiodos em um comprimento de onda de 265 nm. O método demonstrou ser específico 
e linear na faixa de 0,1-10 μg/mL (r =0.9997). As precisões (intra e inter dia) revelaram um desvio 
padrão relativo máximo de 3,51%. O método é robusto considerando mudanças realizadas no fluxo da 
fase móvel, temperatura e marca da coluna. Os limites de detecção e quantificação foram de 10,86 e 
32,78 ng/mL, respectivamente. O método cumpriu os requisitos para ser considerado confiável e viável 
para aplicação na análise quantitativa de 5-FU em nanopartículas poliméricas.
Unitermos: Fluorouracila/determinação. Nanopartículas. Cromatografia líquida de alta eficiências/
análise quantitativa/validação de método.
INTRODUCTION
The fluorouracil (5-FU) is an anticancer agent used 
in the treatment of solid tumors. This drug, an analog of the 
natural pyrimidine uracil, must be converted to the nucleo-
tide to exert its effect. The drug is rapidly metabolized 
after administration, giving cytotoxic fluoronucleotides 
with well-known antineoplastic properties (Pinedo, Peters, 
1988). One explanation for this phenomenon is the possi-
bility that 5-FU pharmacomodulation markedly increases 
the antitumor efficacy of this antimetabolite (Peters, Van 
Groeningein, 1991).
The mechanism of 5-FU cytotoxicity is complex 
because the drug is activated through different pathways 
leading to at least three cytotoxic compounds: fluorode-
oxyuridine monophosphate, which inhibits thymidylate 
synthase and subsequent DNA synthesis; fluorouridine 
triphosphate, which is directly incorporated into RNA; and 
fluorodeoxyuridine triphosphate, for which incorporation 
into DNA has been suggested (Grem, 1990).
The 5-FU presents a narrow therapeutic index, and 
many papers have reported greater variability in pharma-
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cokinetics than other anticancer drugs. For these reasons, 
some inter-patient differences in terms of toxicity and 
efficacy can be expected based on individual pharmaco-
kinetic parameters, especially in the area under the time 
vs. concentration curve (AUC) (Gamelin, Boisdron-Celle, 
1999; Gamelin et al., 1999; Casale et al., 2004). Another 
problem with 5-FU therapy is its toxicity to the bone mar-
row and the gastrointestinal tract (Tanaka et al., 2000; Lai, 
Guo, 2011). Therefore, 5-FU represents an interesting drug 
model to be improved by nanotechnology.
Numerous investigators have shown that the biologi-
cal distribution of drugs, proteins or DNA can be modi-
fied, both at the cellular and organ levels, using micro/
nanoparticle delivery systems (Moghimi et al., 2001; 
Panyam, Labhasetwar, 2003; Labhasetwar, Prabha, 2004; 
Akagi et al., 2005). The nanoencapsulation of drugs has 
many advantages for the protection from premature deg-
radation and interaction with the biological environment, 
enhancement of absorption into a selected tissue, bioavail-
ability, retention time and improvement of intracellular 
penetration. However, polymeric nanoparticles, when used 
intravenously, are removed from systemic circulation by 
the cells of the mononuclear phagocyte system (MPS). 
Several methods are used to modify the surface of the 
nanoparticles to avoid recognition and capture by the cells 
of the MPS and promote a long plasma circulating time 
and improved pharmacokinetics. Among these methods, 
coating nanoparticles with hydrophilic polymers such as 
polyethylene glycol (PEG) is the most popular because the 
long chains of PEG prevent opsonization and phagocytosis 
by steric hindrance (Alexis et al., 2008).
To characterize the delivery systems such as poly-
meric nanoparticles fully, suitable and validated quantita-
tion methods are required to assess pharmaceutical param-
eters such as drug content. Several methods are described 
in the literature for the determination of 5-FU in samples of 
biological matrices using gas chromatography/mass spec-
trometry (GC/MS) (Anderson et al., 1997), spectrometry 
(Badea et al., 2002), high performance liquid chromatog-
raphy (HPLC) (Escoriaza et al., 1999), hydrophilic inter-
action liquid chromatography-APCI-mass spectrometry 
(Pisano et al., 2005) or liquid chromatography tandem 
mass spectrometry (LC–MS/MS) (Licea-Perez, Wang, 
Bowen, 2009; Liu et al., 2010). The analytical determi-
nation of 5-FU in pharmaceutical dosage forms such as 
nanoparticles has been performed by several authors using 
spectrophotometry (Bozkir, Saka, 2005; Liu et al., 2006; 
Zhu et al., 2009; Lai, Guo, 2011; Li et al., 2011; Rejinold et 
al., 2011a; Rejinold et al., 2011b; Zhang et al., 2011), but 
few studies report the use of HPLC methods for this deter-
mination. Arbós, Campanero and Irache (2002) described 
an HPLC method for the quantitation of 5-fluorouridine 
in nanoparticles and verified the possible degradation of 
5-FU, but the investigators used a C8 column. Zheng et al. 
(2007) described an HPLC method using as mobile phase 
a mixture of methanol and 3.6% acetic acid (80:20, v/v), 
but details such as the retention time, peak characteristics 
and validation data were not described.
The objective of this work was therefore to develop 
and validate a fast, simple and optimized HPLC method 
to determine the encapsulation efficiency of 5-FU incor-




Fluorouracil (99% TLC), poly(lactic acid) (PLA) 
(MW 85-160 kDa), polyethylene glycol (10 kDa) and 
polyvinyl alcohol (PVA, 31 KDa, 88% hydrolyzed) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Methylene chloride was purchased from FMaia® (Brazil). 
HPLC-grade acetonitrile was purchased from JTBaker® 
(USA). Water was purified in a Milli-Q Plus system (Mil-
lipore®), and its resistivity was 18.2 MƱ cm. All other 
solvents and chemicals were analytical or HPLC grade.
Instrumentation
A Waters 2695 Alliance HPLC system (Milford, 
MA, USA) was used for method development. The HPLC 
system was equipped with a column compartment with 
temperature control, an on-line degasser, a quaternary 
pump, an auto sampler and a photodiode array (PDA) 
wavelength detector (Waters 2998). Data acquisition, 
analysis, and reporting were performed using Empower 
chromatography software (Milford, MA, USA). HPLC 
analysis was conducted using a RP C18 column (Xterra 
Waters®), with 5 µm particle size, 4.6 mm internal diam-
eter and 250 mm length.
Preparation of standard and sample solutions
A stock standard solution of 500 µg/mL of 5-FU 
was prepared in water and subsequent dilutions were car-
ried out to obtain eight standard solutions (0.1, 0.5, 1.0, 
2.0, 4.0, 6.0, 8.0 and 10.0 μg/mL). Similarly, six standard 
solutions were obtained by serial dilutions of a 5-FU stan-
dard solution (1.0 μg/mL) with water (50.0, 75.0, 100.0, 
125.0, 150.0, and 200.0 ng/mL) to determine the limit of 
detection (LOD) and limit of quantitation (LOQ) for this 
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method. The samples were appropriately diluted in water. 
The standards and samples had previously been filtered 
through a 0.22 μm pore size filter (Millipore, Bedford, 
USA) prior to injection.
Chromatographic conditions
Chromatographic analysis was performed in the 
isocratic mode. The mobile phase consisted of a mixture 
of acetonitrile and water (10:90, v/v), which was pumped 
at a flow rate of 1.0 mL/min. The sample injection volume 
was 100 µL, and the PDA detection wavelength was 265 
nm. The method run time was 4 min, and all experiments 
were performed at 25°C.
Method validation
The HPLC method was validated according to the 
International Conference on Harmonization (ICH) guide-
lines (2005). The following characteristics were consid-
ered for validation: specificity, linearity, range, accuracy, 
precision, LOD, LOQ and robustness.
The specificity was evaluated by comparing the 
representative chromatograms of samples containing pos-
sible interfering substances and samples containing 5-FU. 
Additionally, specificity was demonstrated by performing 
stress studies (i.e., light stability, pH variation, temperature 
and oxidation).
Linearity was determined by calculating a regression 
line from the plot of peak area vs. concentration for the 
eight standard solutions in water (i.e., 0.1, 0.5, 1.0, 2.0, 
4.0, 6.0, 8.0 and 10.0 μg/mL) using the linear least squares 
methodology. 
The accuracy was tested by calculating the percent 
recovery of the mean concentration of 5-FU at three differ-
ent concentration levels, and the relative standard devia-
tion (RSD) was determined. The mean concentration value 
obtained for each level was compared to the theoretical 
value, which was considered to be 100%.
Precision was assessed at two levels: repeatabil-
ity or intra-day variability and intermediate precision or 
inter-day variability. The repeatability was assessed by 
testing three different standard solutions on the same day 
and using a standard solution with concentration of 1.0 
μg/mL analyzed 10 times in succession. The results were 
reported as RSD. The intermediate precision was evalu-
ated by analyzing three different standard samples on two 
different days. The results were reported as the standard 
deviation (SD) and RSD.
The LOD and LOQ were determined from the spe-
cific calibration curve obtained using six standard solu-
tions (50.0, 75.0, 100.0, 125.0, 150.0, and 200.0 ng/mL) 
that were the closest to the LOQ. The following equations 
(1 and 2) were used according to ICH (2005):
 LOD=3.3/σ.S Eq. 1
 LOQ=10/σ.S Eq. 2
where σ is the standard deviation of the response, and S is 
the slope of the calibration curve.
Robustness was evaluated by deliberately varying 
the temperature of the analytical column (35 °C), the flow 
rate (0.9 and 1.1 mL/min) and using a similar C18 column 
(5 μm particle size, 4.6 mm internal diameter, and 250 mm 
length; Vertical Chromatography Co.®).
Method applicability
Preparation of 5-FU-loaded PLA or PLA-PEG blended 
nanoparticles
The nanoparticles were obtained using the double 
emulsion solvent-evaporation technique (Zabaux et al., 
1998). Initially, PLA was dissolved in methylene chloride 
either with or without PEG at room temperature. This 
solution was poured rapidly into a PVA aqueous solution 
containing 5-FU and emulsified by means of sonication for 
1 min (35% of 500W, Unique® Ultrasonic Mixing, mod. 
DES 500, equipped with a 4 mm probe, Unique Group, 
Brazil). The resulting water-in-oil (W/O) emulsion was 
further emulsified with PVA aqueous solution by sonica-
tion for 5 min, resulting in a water-in-oil-in-water emulsion 
(W/O/W). Next, the organic solvent was rapidly eliminated 
by evaporation under vacuum at 37 ºC. The particles were 
then recovered by ultracentrifugation (19,975 g, 30 min, 
4 °C, Cientec CT-15000R centrifuge, Brazil) and washed 
twice with water to remove the surfactant. The nanoparticles 
were dispersed in the cryoprotectant sucrose, and the result-
ing nanosuspension was subsequently cooled to −18 °C and 
freeze-dried (Terroni, Brazil). All details presented here are 
under patent, as requested in Brazil, and must be protected 
according to the Brazilian agency regulation.
The mean particle size, size distribution and poly-
dispersity index were determined by dynamic light scat-
tering (BIC 90 plus, Brookhaven Instruments Corp.). The 
analyses were performed at a scattering angle of 90° and a 
temperature of 25 °C. For each sample, the mean particle 
diameter, polydispersity and standard deviation for ten 
determinations were calculated.
Determination of the 5-FU encapsulation
The amount of 5-FU incorporated into the nanopar-
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ticles was determined indirectly (Das Neves et al., 2010). 
The analyte was the supernatant, which contained free 5-FU 
separated from solid nanoparticles by ultracentrifugation.
After appropriate dilutions in water, 100 μL of the 
sample was injected into the HPLC system, and the drug 
concentration in the supernatant was obtained by compar-
ing the concentration obtained to a previously constructed 
analytical curve. Before injection, all solutions were fil-
tered through a membrane filter (0.22-μm pore size, Mil-
lipore). The amount of 5-FU entrapped in the nanoparticles 
was obtained by subtracting the amount in the supernatant 
from the total amount used during the preparation. These 
analyses were performed in triplicate.
RESULTS AND DISCUSSION
Method development
Due to the high aqueous solubility of 5-FU, hydro-
philic solvents were used to reduce the affinity of the drug 
for the column and thus obtain short retention times. 
Initially, the methodology described in the United 
States Pharmacopoeia USP 34 (2010) was tested, describing 
ultrapure water as mobile phase, with a rate of 1.0 mL/min. 
However, for samples, irregular peaks were observed us-
ing low resolution chromatography (Figure 1A), possibly 
because of instrumental or column differences.
Acetonitrile was added to the mobile phase to 
improve the resolution of chromatographic peaks of 
5-FU. Analyses were performed using acetonitrile and 
water in many proportions, in isocratic mode and with 
the proportions of acetonitrile:water ranging from 10:90 
(v/v) to 70:30 (v/v). Noticeable tailing and an irregular 
shape of the 5-FU peak were observed when the propor-
tion of acetonitrile was higher than the water. Increas-
ing the water proportion in the mobile phase, the 5-FU 
peak became more regular, and, when the proportion of 
acetonitrile:water of 10:90 (v/v) was used, a regular and 
FIGURE 1 - Representative HPLC chromatograms of 1.0 μg/mL 5-FU standard solution, using 100% ultrapure water as the mobile 
phase (A) and acetonitrile and water (10:90, v/v) as the mobile phase (B).
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FIGURE 2 - Representative HPLC chromatograms of the PVA aqueous solution (1% (w/v)) (A) and supernatant from the production 
of 5-FU nanoparticles (B).
symmetric peak was observed. Under these conditions, 




The PVA aqueous solution (i.e., the main component 
of supernatant obtained by ultracentrifugation of an aque-
ous dispersion of nanoparticles) was analyzed using the 
HPLC method described (Figure 2A) and compared with 
the chromatogram of the 5-FU standard (Figure 1B) and 
5-FU sample (5-FU in supernatant) (Figure 2B). A peak at 
the 5-FU retention time was observed in the chromatogram 
of the PVA aqueous solution, but the peak is so small that 
it does not interfere with the quantitative determination of 
5-FU from the formulation components. To confirm this 
observation, a 5-FU standard solution prepared in PVA 
aqueous solution was analyzed and compared to the 5-FU 
standard solution in water (as usual). The percent recovery 
of 5-FU in PVA aqueous solution was 99.89%. 
Tests were also performed under four stress condi-
tions (i.e., temperature, visible light, pH and oxidation) 
to detect the occurrence of possible interfering peaks at 
265 nm resulting from the degradation of 5-FU. These tests 
are regarded as helpful tools in establishing degradation 
pathways and the inherent stability of the molecule and 
help validate the power of the method for studying the drug 
stability (Das Neves et al., 2010). The percent recovery 
under stress conditions also revealed that 5-FU was not 
affected, except at high pH values (4.23%). The results 
obtained are presented in Table I, showing no alterations 
in 5-FU retention time. 
Linearity
Linearity was evaluated at eight concentration levels 
ranging from 0.1 to10 μg/mL by calculating the regression 
equation (Eq. 3) and the correlation coefficient (r) using 
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the method of least squares:
 Y = 0.041259 × A − 4.66.104 Eq. 3
 r = 0.9997
where Y is the peak area and A is the standard solution 
concentration in μg/mL. The r -value near 1 indicates 
linearity in the proposed range.
The validity of the assay was confirmed by an analy-
sis of variance, which showed that the linear regression 
was significant and the deviation from linearity was not 
significant (p <0.01).
Accuracy
Accuracy was assessed by calculating the percent 
recovery and the RSD of the mean concentration of the 
analyte at three different concentrations. Three standard 
solutions (0.1, 1 and 10 μg/mL) were carefully prepared 
in triplicate and analyzed using the proposed method. 
Detailed results for these three tested concentration levels 
are presented in Table II. The mean percent recovery of 
5-FU from the samples was 99.95% (RSD = 1.49%, n = 9). 
The results show agreement between experimental and 
theoretical values. 
Precision
The precision is a measure of the relative errors of 
the method, expressed as the RSD for repeatability and 
intermediate precision. Three concentrations of 5-FU (0.1, 
1 and 10 μg/mL) were prepared in triplicate and analyzed 
on one day or two different days to evaluate intra-day or 
inter-day variation, respectively. The RSDs of responses 
were calculated in each case and are shown in Table III, 
indicating that precision was obtained because the maxi-
mal RSD obtained was 3.51%.
The instrumental precision is a measure of the rela-
tive errors inherent in the equipment and is expressed as the 
RSD for repeatability. One standard of 5-FU (1.0 μg/mL) 
was prepared and analyzed in one day (n=10). The results 
indicate the instrument precision (percent recovery = 
98.57%) because the maximum RSD obtained was 0.13%.
Limits of quantification and detection
The lowest concentration at which an analyte can 
TABLE I - Results of exposure of 5-FU standards solutions to stress conditions (n=3)
Conditions
Percentage of Recovery ± RSD
0.1 µg/mL 1.0 µg/mL 10.0 µg/mL Mean
Reference 99.60 ± 1.80 104.26 ± 3.82 104.56 ± 0.73 102.81 ± 2.11
UV light 104.46 ± 3.50 107.50 ± 2.42 103.90 ± 0.49 105.28 ± 2.13
Congealment 103.30 ± 2.65 105.36 ± 0.81 103.20 ± 1.00 103.95 ± 1.48
High pH 0.00 ± 35.07 10.36 ± 38.05 2.33 ± 38.63 4.23 ± 37.25
Low pH 100.46 ± 0.32 109.06 ± 3.61 103.13 ± 1.05 104.22 ± 1.66
Oxidation 100.46 ± 0.61 106.23 ± 1.46 104.60 ± 0.02 107.09 ± 0.69
TABLE II - Accuracy results for 5-FU concentrations in the 
standard solutions
Standard solution 













0.1 0.09 ± 0.02 1.87
1.0 0.98 ± 0.00 0.17
10.0 9.97 ± 0.13 1.27
Intermediate precision (n=3)
Day 1
0.1 0.09 ± 0.00 1.46
1.0 0.95 ± 0.02 2.11
10.0 10.14 ± 0.07 0.70
Day 2
0.1 0.09 ± 0.00 1.66
1.0 1.04 ± 0.04 3.51
10.0 10.46 ± 0.07 0.63
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TABLE IV - Robustness results for different flow rate, column brand and temperature
Changes to original 
method*
Percentage of Recovery ± RSD
0.1 µg/mL 1.0 µg/mL 10.0 µg/mL Mean
None 99.55 ± 1.87 98.57 ± 0.17 99.71 ± 1.27 99.28 ± 1.10
Flow rate: 0.9 mL/min 104.80 ± 3.48 103.53 ± 2.22 99.23 ± 1.76 102.52 ± 2.48
Flow rate: 1.1 mL/min 107.36 ± 3.44 102.40 ± 2.30 100.40 ± 1.05 103.38 ± 2.27
Similar column 97.33 ± 0.01 105.50 ± 0.06 106.56 ± 0.65 103.13 ± 0.24
Column Temperature: 
35 °C
98.43 ± 0.00 105.90 ± 0.04 97.85 ± 0.77 100.72 ± 0.27
* 1.0mL/min, column at 25 °C and mobile phase (acetonitrile:water 10:90, v/v).
be detected (LOD) or quantified (LOQ) with acceptable 
precision and accuracy, in the present study, was calcu-
lated from the SD of the response and the slope obtained 
from linear regression of a specific calibration curve 
(50-200 ng/mL) in the low-end region of the proposed 
range (ICH, 2005). The method was linear in this range 
because the r-value was 0.993. The LOD and LOQ were 
found to be 10.86 and 32.78 ng/mL, respectively.
Range
The working range of the method, defined as the 
range that possesses the required linearity, accuracy and 
precision, was between the LOQ and 10 μg/mL. Samples 
containing these concentration levels may therefore be 
assayed using the proposed HPLC method.
Robustness
Robustness is a measure of the influence of small 
changes in the analytical procedures/parameters on the 
response. The evaluation of robustness was based on the 
percent recovery and RSD values obtained using differ-
ent parameters for flow rate of mobile phase and column 
temperature and using a similar C18 column. The method 
is robust concerning these alterations in chromatographic 
parameters (Table IV). The maximum RSD obtained was 
3.48%.
Method applicability
The proposed analytical method was used to evalu-
ate the content of 5-FU in PLA and PLA-PEG blended 
nanoparticles. An indirect method, which separated the 
supernatant containing free 5-FU from the solid nanopar-
ticles by ultracentrifugation, was used. The supernatant 
was analyzed using HPLC. As shown in the specificity 
test, no alterations to the chromatograms or unusual peaks 
were observed during the drug quantification. 
The method of double emulsion-solvent evaporation 
was adequate to obtain the nanoparticles containing 5-FU. 
The main characteristics of the nanoparticles are described 
in Table V. The presence of PEG did not influence the en-
capsulation efficiency because both nanoparticles showed 
the same efficiency in loading the 5-FU. Considering the 
particle size, the PEG provided a slight increase in particle 
size compared with PLA nanoparticles (p<0.05), but both 
formulations presented a bimodal distribution profile. 
Nanoparticles can be considered potential carriers for 
5-FU delivery.
Our objective was to develop a fast, simple and ef-
fective HPLC-PDA method for quantitative analyses of 
5-FU in PLA and PLA-PEG blended nanoparticles. The 
literature describes mainly spectrophotometric methods 
for 5-FU quantitation in nanoformulations (Bozkir, Saka, 
TABLE V - Nanoparticle characteristics
Nanoparticle Mean size (nm)ª Polydispersity indexª Size distributionª Encapsulation 
efficiency (%)ª
PLA 282.87 ± 3.64 0.116 195-233 nm (54%) and 398-476 nm (46%) 51.23 ± 7.82
PLA-PEG 305.80 ± 3.62 0.173 171-208 nm (39%) and 432-525 nm (61%) 55.53 ± 9.21
ª Values reported as mean ± S.D. (n=3).
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2005; Liu et al., 2006; Zhu et al., 2009; Lai, Guo, 2011; 
Li et al., 2011; Rejinold et al., 2011a; Rejinold et al., 
2011b; Zhang et al., 2011), but these methods are not as 
convenient as HPLC methods considering the sensitivity. 
The only example in the literature of an HPLC-UV method 
applied to 5-FU determination in nanoparticles was the 
method cited by Zheng et al. (2007), but the authors cited 
only the mobile phase (methanol:3.6% acetic acid - 80:20, 
v/v) and did not give any information about validation data 
and retention time of 5-FU. Arbós, Campanero and Irache 
(2002) developed an HPLC-UV method for quantitation of 
5-fluorouridine in nanoparticles and, in addition to other 
parameters, verified whether this drug degrades in 5-FU. 
The mobile phase was comprised of 0.05 M ammonium 
acetate (pH 6.5), and the results showed a retention time 
of 6.7 min for 5-fluorouridine and 4.5 min for 5-FU. The 
method was sensitive and could be applied to 5-FU, but a 
C8 column was used, so the method does not correspond 
to our chromatographic conditions. Thus, the HPLC-PDA 
method developed and validated in this work represents 
an alternative to spectrophotometric methods for the 
analysis of 5-FU in nanoparticles and fulfills the require-
ment for detailed data in the literature for analyzing 5-FU 
in nanoparticles via HPLC-PDA detection. The proposed 
method could be applied not only for the determination 
of encapsulation efficiency of 5-FU in nanoparticles but 
also for other assays, such as determining the in vitro 5-FU 
release profile and stability studies.
CONCLUSION
A fast, simple and reliable HPLC method using 
photodiode array detection for determining the encapsu-
lation efficiency of 5-FU in PLA and PLA-PEG blended 
nanoparticles has been developed and validated according 
to the ICH guidelines. The method fulfilled the require-
ments to be considered a reliable and feasible method, 
including specificity, linearity, precision, accuracy, 
robustness, LOD and LOQ. The analytical procedure 
has a chromatographic run time of 4 min, which allows 
analyzing a large number of samples in a short period of 
time. The low percentage of acetonitrile used is important 
because it reduces the cost of solvent and the damage to 
the environment. This method was found to be suitable for 
determining 5-FU encapsulation efficiency in polymeric 
nanoparticles.
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